{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:07:34Z","timestamp":1788930454974,"version":"build-2803163510"},"reference-count":111,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Cancer-associated thrombosis (CAT) is still a leading cause of morbidity and mortality in patients with malignancy and represents a major challenge in cardio-oncology. Although low-molecular-weight heparins (LMWH) have long been the standard of care, direct oral anticoagulants (DOACs) have broadened treatment options. However, balancing thrombotic and bleeding risks, accounting for tumor- and individual-specific characteristics, requires an individualized therapeutic approach. This review summarizes current evidence supporting personalized anticoagulation strategies in CAT. Materials and Methods: A structured narrative review supported by a systematic literature search was conducted. Evidence regarding LMWH, DOACs, and emerging factor XI\/XIa inhibitors was critically appraised, with emphasis on clinical scenarios necessitating individualized management, including gastrointestinal, genitourinary, and intracranial malignancies, hepatocellular carcinoma, thrombocytopenia, renal impairment, drug\u2013drug interactions, and recurrent thrombosis. Results: Both LMWH and DOACs are effective options for CAT, with treatment selection guided by the balance between thrombotic and bleeding risks. Among DOACs, apixaban appears to have a favorable efficacy\u2013safety profile based on current evidence, whereas rivaroxaban and edoxaban remain suitable for carefully selected patients despite higher bleeding risk in specific settings. LMWH continues to be preferred in patients with active mucosal tumors, severe thrombocytopenia, advanced renal dysfunction, significant drug\u2013drug interactions, or when dosing flexibility is required. Emerging evidence also points to possible pleiotropic effects of DOACs on inflammation, angiogenesis, and metastatic progression, although the results have not yet translated into proven clinical benefit. Factor XI\/XIa inhibitors remain investigational, with no established role in cancer-associated thrombosis. Conclusions: Contemporary CAT management has shifted toward personalized anticoagulant selection based on tumor characteristics, bleeding risk, organ function, anticancer therapy, and patient-related factors. Future advances, including factor XI\/XIa inhibitors and a better understanding of anticoagulants\u2019 biological effects beyond thrombosis prevention, may further optimize individualized treatment and improve clinical outcomes.<\/jats:p>","DOI":"10.3390\/medicina62091677","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:05:26Z","timestamp":1788224726000},"page":"1677","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Personalized Anticoagulation in Cancer Patients: Current Evidence and Future Perspectives"],"prefix":"10.3390","volume":"62","author":[{"given":"\u0218tefan","family":"Chiorescu","sequence":"first","affiliation":[{"name":"Department of Surgery, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"Department of Surgery, Emergency Clinical County Hospital, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5906-8024","authenticated-orcid":false,"given":"Mihaela","family":"Mocan","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"Department of Internal Medicine, Emergency Clinical County Hospital, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Patricia","family":"Dinic\u0103","sequence":"additional","affiliation":[{"name":"\u201cProf. Dr. Octavian Fodor\u201d Regional Institute of Gastroenterology and Hepatology, 400162 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu Nicolae","family":"Grad","sequence":"additional","affiliation":[{"name":"Department of Surgery, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"Department of Surgery, Dr. Constantin Papilian Military Emergency Clinical Hospital, 400394 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3097-707X","authenticated-orcid":false,"given":"Vlad-Ionu\u021b","family":"Nechita","sequence":"additional","affiliation":[{"name":"Department of Fundamental Sciences, Discipline of Medical Informatics, Research Methodology and Data Analysis, Faculty of Nursing and Health Sciences (FAMSS), Iuliu Ha\u021bieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana Mihaela","family":"Chiorescu","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"Department of Internal Medicine, Emergency Clinical County Hospital, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Chiorescu, R.M., Mocan, M., Stoia, M.A., Barta, A., Goidescu, C.M., Chiorescu, S., and Farca\u015f, A.D. (2021). Arguments for using direct oral anticoagulants in cancer-related venous thromboembolism. Healthcare, 9.","DOI":"10.3390\/healthcare9101287"},{"key":"ref_2","first-page":"e83956","article-title":"The role of direct oral anticoagulants (DOACs) in cancer-associated thrombosis: A comprehensive review of the literature","volume":"17","author":"Qureshi","year":"2025","journal-title":"Cureus"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jacc.2019.01.017","article-title":"Anticoagulation strategies in patients with cancer: JACC review topic of the week","volume":"73","author":"Mosarla","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer-associated venous thromboembolism: Burden, mechanisms, and management","volume":"117","author":"Ay","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1160\/TH15-08-0686","article-title":"Epidemiology of first and recurrent venous thromboembolism in patients with active cancer: A population-based cohort study","volume":"117","author":"Cohen","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/153100350401600217","article-title":"Low-molecular-weight heparin versus coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"16","author":"Tonnessen","year":"2004","journal-title":"Perspect. Vasc. Surg. Endovasc. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs dalteparin in cancer-associated thromboembolism: A randomized trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-022-01289-1","article-title":"Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Frere","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_14","unstructured":"National Comprehensive Cancer Network (2025). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Cancer-Associated Venous Thromboembolic Disease. Version 3, National Comprehensive Cancer Network."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jtha.2024.03.011","article-title":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial","volume":"22","author":"McBane","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose apixaban for cancer-associated venous thromboembolism","volume":"392","author":"Carrier","year":"2025","journal-title":"N Engl. J. Med."},{"key":"ref_17","first-page":"S22","article-title":"CONKO-011: Evaluation of patient satisfaction with the treatment of acute venous thromboembolism with rivaroxaban or low molecular weight heparin in cancer patients. A randomized phase III study","volume":"140","author":"Riess","year":"2015","journal-title":"Dtsch. Med. Wochenschr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1159\/000545976","article-title":"CONKO-011\/AIO-SUP-0115\/ass.: Rivaroxaban compared to low molecular weight heparin in cancer patients with acute venous thromboembolism","volume":"48","author":"Sinn","year":"2025","journal-title":"Oncol. Res. Treat."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Mauriello, A., Maratea, A.C., Fonderico, C., Quagliariello, V., Maurea, F., and Maurea, N. (2025). Factor XI and cancer: Physiopathological linkage and clinical perspectives. J. Clin. Med., 14.","DOI":"10.3390\/jcm14176341"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Campello, E., Simioni, P., Prandoni, P., and Ferri, N. (2022). Clinical pharmacology of factor XI inhibitors: New therapeutic approaches for prevention of venous and arterial thrombotic disorders. J. Clin. Med., 11.","DOI":"10.3390\/jcm11216314"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb. Haemost."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1161\/STROKEAHA.119.026545","article-title":"Leveraging human genetics to estimate clinical risk reductions achievable by inhibiting factor XI","volume":"50","author":"Georgi","year":"2019","journal-title":"Stroke"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jtha.2023.09.015","article-title":"Effect of factor XI inhibition on tumor cell-induced coagulation activation","volume":"22","author":"Rolling","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_25","unstructured":"ClinicalTrials.gov (2021). A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-Associated VTE (ASTER), U.S. National Library of Medicine. Available online: https:\/\/clinicaltrials.gov\/study\/NCT05171049."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.31083\/j.rcm2410295","article-title":"Abelacimab in cancer-associated thrombosis: The right drug at the right time for the right purpose. A comprehensive review","volume":"24","author":"Fioretti","year":"2023","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_27","unstructured":"ClinicalTrials.gov (2026). REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis (ROXI-CAT-I), U.S. National Library of Medicine. Available online: https:\/\/clinicaltrials.gov\/study\/NCT07410117."},{"key":"ref_28","unstructured":"ClinicalTrials.gov (2026). Treatment and Secondary Prevention of Venous Thromboembolism in Adult Participants with Solid and Hematologic Cancers (ROXI-CAT-II), U.S. National Library of Medicine. Available online: https:\/\/clinicaltrials.gov\/study\/NCT07493304."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/ATVBAHA.123.319692","article-title":"Factor XI inhibition for the prevention of catheter-associated thrombosis in patients with cancer undergoing central line placement: A phase 2 clinical trial","volume":"44","author":"Pfeffer","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102898","DOI":"10.1016\/j.rpth.2025.102898","article-title":"Strategies for anticoagulation in patients with thrombocytopenia and cancer-associated thrombosis (START): Design and rationale of the START pilot randomized controlled trial","volume":"9","author":"Wang","year":"2025","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"17562872251315930","DOI":"10.1177\/17562872251315930","article-title":"Risk of postoperative bleeding and thromboembolic events in anticoagulated patients undergoing transurethral resection of bladder tumors","volume":"17","author":"Scherer","year":"2025","journal-title":"Ther. Adv. Urol."},{"key":"ref_32","first-page":"vdaf205","article-title":"Intracerebral hemorrhage risk in glioma patients taking direct oral anticoagulants as compared with low molecular weight heparin","volume":"7","author":"Amin","year":"2025","journal-title":"Neurooncol Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4174\/astr.2025.108.3.168","article-title":"Safety and effectiveness of direct oral anticoagulants in fragile patients with venous thromboembolism: A retrospective cohort observational study","volume":"108","author":"Park","year":"2025","journal-title":"Ann. Surg. Treat. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s11239-024-02992-1","article-title":"Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: A Swedish national population-based register study","volume":"57","author":"Linder","year":"2024","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e70266","DOI":"10.1002\/cncr.70266","article-title":"Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents","volume":"132","author":"Wang","year":"2026","journal-title":"Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5489\/cuaj.9312","article-title":"Comparative analysis of apixaban vs. enoxaparin for thromboprophylaxis after radical cystectomy: A single-center, observational, before-after study","volume":"19","author":"Macklin","year":"2025","journal-title":"Can. Urol. Assoc. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100140","DOI":"10.1016\/j.bvth.2026.100140","article-title":"Intracranial hemorrhage in patients with primary brain cancer receiving anticoagulation","volume":"3","author":"Wang","year":"2026","journal-title":"Blood Vessel. Thromb. Hemost."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.jtha.2025.02.022","article-title":"Treatment and outcomes after on-treatment recurrent venous thromboembolism in patients with cancer: A post hoc analysis of the Hokusai venous thromboembolism cancer study","volume":"23","author":"Lanting","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1016\/j.jtha.2025.08.022","article-title":"Management of recurrent venous thromboembolism during anticoagulant treatment in patients with cancer: A prospective cohort study","volume":"23","author":"Lanting","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1038\/s41467-024-50037-1","article-title":"Effectiveness and safety of continuous low-molecular-weight heparin versus switching to direct oral anticoagulants in cancer-associated venous thrombosis","volume":"15","author":"Kang","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bjh.19414","article-title":"Cancer-associated venous thrombosis in adults (second edition): A British Society for Haematology guideline","volume":"205","author":"Alikhan","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1007\/s12094-024-03605-2","article-title":"SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023)","volume":"26","author":"Mateo","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.rce.2024.09.003","article-title":"2024 Spanish Society of Internal Medicine (SEMI) recommendations for the management of cancer-associated venous thromboembolism","volume":"225","author":"Villalobos","year":"2025","journal-title":"Rev. Clin. Esp."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"483","DOI":"10.6004\/jnccn.2024.0046","article-title":"Cancer-associated venous thromboembolic disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Streiff","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejim.2024.04.012","article-title":"Direct oral anticoagulant-associated bleeding complications in patients with gastrointestinal cancer and venous thromboembolism","volume":"127","author":"Nishimoto","year":"2024","journal-title":"Eur. J. Intern Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12959-025-00789-7","article-title":"Direct oral anticoagulants compared to low molecular weight heparin for the treatment of venous thromboembolism among individuals with gastrointestinal cancer: An updated meta-analysis","volume":"23","author":"Ren","year":"2025","journal-title":"Thromb. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00384-025-05002-9","article-title":"The efficacy and safety of extended thromboprophylaxis after colorectal surgery: A systematic review and meta-analysis","volume":"40","author":"Choi","year":"2025","journal-title":"Int. J. Colorectal Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e70099","DOI":"10.1002\/bco2.70099","article-title":"Gross haematuria in the era of anticoagulant therapy: Implications on treatment and diagnostic approaches in a large emergency department patient population","volume":"6","author":"Yang","year":"2025","journal-title":"BJUI Compass"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00464-023-10649-y","article-title":"Direct oral anticoagulants (DOACs) versus low-molecular-weight heparin (LMWH) for extended thromboprophylaxis following major abdominal\/pelvic cancer-related surgery: A systematic review and meta-analysis","volume":"38","author":"Zhou","year":"2024","journal-title":"Surg. Endosc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jtha.2025.10.020","article-title":"Outcomes of anticoagulation treatment for renal cell carcinoma tumor thrombi: A systematic review","volume":"24","author":"Akerboom","year":"2026","journal-title":"J. Thromb. Haemost."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Alfehaid, L., Alatmi, S., Alfadhel, B., Alqahtani, R., bin Nafisah, S., Alotaibi, Y., AlSheef, M., and Alsuhebany, N. (2026). Anticoagulant outcomes in managing tumor thrombus: A systematic review. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1773327"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/cncr.35220","article-title":"Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients","volume":"130","author":"Ranjan","year":"2024","journal-title":"Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood.2023023450","article-title":"How I treat acute venous thromboembolism in patients with brain tumors","volume":"144","author":"Leader","year":"2024","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/hematology.2024000660","article-title":"Management of anticoagulation in patients with brain metastasis","volume":"2024","author":"Leader","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Boccatonda, A., Gentilini, S., Zanata, E., Simion, C., Serra, C., Simioni, P., Piscaglia, F., Campello, E., and Ageno, W. (2024). Portal vein thrombosis: State-of-the-art review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13051517"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00535-021-01788-x","article-title":"Evidence-based clinical practice guidelines for liver cirrhosis 2020","volume":"56","author":"Yoshiji","year":"2021","journal-title":"J. Gastroenterol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1016\/j.jtha.2024.05.023","article-title":"Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: Guidance from the SSC of the ISTH","volume":"22","author":"Carlin","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2022). EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J. Hepatol., 76, 1151\u20131184.","DOI":"10.1016\/j.jhep.2021.09.003"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.cgh.2020.08.007","article-title":"Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis","volume":"19","author":"Mort","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1053\/j.gastro.2024.10.038","article-title":"AGA Clinical Practice Update on management of portal vein thrombosis in patients with cirrhosis: Expert review","volume":"168","author":"Davis","year":"2025","journal-title":"Gastroenterology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.hbpd.2023.10.009","article-title":"Comprehensive review of hepatocellular carcinoma with portal vein tumor thrombus: State of art and future perspectives","volume":"23","author":"Gavriilidis","year":"2024","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_64","first-page":"47","article-title":"Neurohumoral, cardiac and inflammatory markers in the evaluation of heart failure severity and progression","volume":"18","author":"Polyakova","year":"2021","journal-title":"J. Geriatr. Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Li, H.-J., Yin, F.-Q., Ma, Y.-T., Gao, T.-Y., Tao, Y.-T., Liu, X., Shen, X.-F., and Zhang, C. (2025). Administration of anticoagulation strategies for portal vein thrombosis in cirrhosis: Network meta-analysis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1462338"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Chiorescu, S., Oiegar, R., Mocan, M., Trif, M., Ciocan, R.A., and Chiorescu, R.M. (2026). Case report: Upper extremity deep vein thrombosis revealing an occult invasive ductal breast carcinoma. Front. Cardiovasc. Med., 13.","DOI":"10.3389\/fcvm.2026.1742549"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.thromres.2021.12.025","article-title":"Contemporary breast cancer treatment-associated thrombosis","volume":"213","author":"Kirwan","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jtha.2022.12.001","article-title":"Cyclin-dependent kinase 4\/6 inhibitor-associated thromboembolism: A critical evaluation of the current evidence","volume":"21","author":"Watson","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"109087","DOI":"10.1016\/j.thromres.2024.109087","article-title":"Venous thromboembolism in women with hormone-dependent breast cancer. To continue or discontinue hormonal treatment? Insights from the RIETE registry","volume":"241","author":"Molina","year":"2024","journal-title":"Thromb. Res."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Kozhukhov, S., Dovganych, N., Lygyrda, O., Smolanka, I., Loboda, A., and Lyalkin, S. (2026). Cancer-associated thrombosis in breast cancer: Risk factors and personalized management. J. Clin. Med., 15.","DOI":"10.3390\/jcm15031161"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/hematology.2024000551","article-title":"Treatment of VTE in the thrombocytopenic cancer patient","volume":"2024","author":"Moik","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1007\/s11239-025-03188-x","article-title":"Anticoagulant therapy in patients with cancer and thrombocytopenia","volume":"58","author":"Szmit","year":"2025","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"102684","DOI":"10.1016\/j.rpth.2025.102684","article-title":"Anticoagulant management of cancer-associated thrombosis and thrombocytopenia: A retrospective chart review","volume":"9","author":"Abbas","year":"2025","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_74","first-page":"1849","article-title":"Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer","volume":"109","author":"Patell","year":"2024","journal-title":"Haematologica"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: Guidance from the SSC of the ISTH","volume":"16","author":"Bannow","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.acvd.2023.11.009","article-title":"Management of cancer-associated thromboembolism in vulnerable population","volume":"117","author":"Laporte","year":"2024","journal-title":"Arch. Cardiovasc Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/03007995.2024.2313092","article-title":"Effectiveness and safety of anticoagulants among patients with venous thromboembolism and active cancer who also had prior bleed or prior renal disease","volume":"40","author":"Cohen","year":"2024","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Robotin, M., Olver, I., and Girgis, A. (2009). Cancer and thrombosis. When Cancer Crosses Disciplines: A Physician\u2019s Handbook, Imperial College Press.","DOI":"10.1142\/9781848163652"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Parker, K., Power, A., Bernes, Y., Bramham, K., Buka, R., Choudhuri, S., Davies, M., Gauci, A.M., Hall, L., and Hancock, A. (2025). Clinical Practice Guideline: Anticoagulation for Venous Thromboembolism in Adults with Advanced Kidney Disease, UK Kidney Association.","DOI":"10.1186\/s12882-026-05270-9"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12959-023-00576-2","article-title":"Efficacy and safety of anticoagulant for treatment and prophylaxis of VTE patients with renal insufficiency: A systemic review and meta-analysis","volume":"22","author":"Ma","year":"2024","journal-title":"Thromb. J."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Nowinski, K., and Chaireti, R. (2025). Discrepancies in recommendations on pharmacokinetic drug interactions for anticancer medications and direct oral anticoagulants (DOAC): A comparative analysis of different clinical decision support systems and sources. Pharmaceuticals, 18.","DOI":"10.3390\/ph18071044"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Svalastoga, M., Larsen, T.-L., Brekke, J., Enden, T., Fr\u00f8en, H., Garresori, H., Jacobsen, E.M., Porojnicu, A.C., Ree, A.H., and Torfoss, D. (2025). Effect of drug interactions with apixaban on clinical outcomes in cancer patients with venous thromboembolism. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1520725"},{"key":"ref_83","first-page":"17310","article-title":"Levels of direct oral anticoagulants in cancer patients undergoing chemotherapy","volume":"136","author":"Firkowska","year":"2026","journal-title":"Pol. Arch. Intern Med."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Althiab, K., Aljohani, M., Alraddadi, S., and Algarni, M. (2022). Capecitabine and warfarin interaction: A case report with review of literature and management options. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.707361"},{"key":"ref_85","unstructured":"DailyMed (2025). GLEOSTINE (Lomustine) Capsule, Gelatin Coated: Prescribing Information, Azurity Pharmaceuticals, Inc.. Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=3529fe2f-3c23-4862-bb20-b48026957082."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Leblanc, K., Edwards, S.J., Dranitsaris, G., Leong, D.P., Carrier, M., Malone, S., Rendon, R.A., Bond, A.M., Sitland, T.D., and Zalewski, P. (2024). Drug interactions between androgen receptor axis-targeted therapies and antithrombotic therapies in prostate cancer: Delphi consensus. Cancers, 16.","DOI":"10.3390\/cancers16193336"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Liao, D., Zhao, Y., Jin, Y., Long, M., Wang, S., and Chen, S. (2026). Exploratory assessment of bleeding risk associated with concurrent use of anti-VEGF agents and anticoagulants in oncology. Front. Pharmacol., 17.","DOI":"10.3389\/fphar.2026.1759971"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.31557\/APJCP.2025.26.6.1931","article-title":"Impact of olaparib, niraparib, rucaparib therapies on newly diagnosed and relapsed ovarian cancer: Systematic review and meta-analysis","volume":"26","author":"Devi","year":"2025","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejogrb.2024.12.021","article-title":"Haematological toxicity of PARP inhibitors in advanced ovarian cancer: A systematic review and meta-analysis","volume":"305","author":"Loizzi","year":"2025","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e390876","DOI":"10.1200\/EDBK_390876","article-title":"Managing adverse effects associated with poly (ADP-ribose) polymerase inhibitors in ovarian cancer: A synthesis of clinical trial and real-world data","volume":"43","author":"Friedlander","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Luo, H., Fan, S., Liang, L., He, Y., Chen, J., Xu, C., Zhu, J., and Zhang, L. (2025). Adverse event profile of lomustine and temozolomide: A descriptive analysis from WHO-VigiAccess. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1534802"},{"key":"ref_92","first-page":"678","article-title":"Severe temozolomide-induced thrombocytopenia is linked to increased healthcare utilization in glioblastoma and disproportionally impacts female patients","volume":"12","author":"Borgo","year":"2025","journal-title":"Neurooncol. Pract."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Kania, J., Zawadzki, J., Kudli\u0144ski, B., and Zi\u00f3\u0142kowska, W. (J. Thromb. Thrombolysis, 2026). Early catheter-related thrombosis in oncology patients with central venous access devices: A narrative review of incidence, mechanisms and clinical implications, J. Thromb. Thrombolysis, online ahead of print.","DOI":"10.1007\/s11239-026-03338-9"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Rubio, M., Lago-Rodr\u00edguez, M.-O., Ordieres-Ortega, L., Oblitas, C.-M., Morag\u00f3n-Ledesma, S., Alonso-Beato, R., Alvarez-Sala-Walther, L.-A., and Galeano-Valle, F. (2024). A comprehensive review of catheter-related thrombosis. J. Clin. Med., 13.","DOI":"10.3390\/jcm13247818"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e14311","DOI":"10.1111\/eci.14311","article-title":"Catheter-related deep vein thrombosis: Where are we at and where are we going? Updates and ongoing unmet clinical needs","volume":"55","author":"Girardi","year":"2025","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.7150\/jca.103631","article-title":"Implantable port catheters versus peripherally inserted central catheters for cancer patients requiring chemotherapy: An RCT-based meta-analysis","volume":"16","author":"Qiu","year":"2025","journal-title":"J. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"100191","DOI":"10.1016\/j.tru.2024.100191","article-title":"Catheter-related thrombosis in cancer patients: Data from the registry of thrombosis and nEoplasia of SEOM (TESEO)","volume":"17","author":"Mateo","year":"2024","journal-title":"Thromb. Updat."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jtha.2023.11.017","article-title":"Management of catheter-related upper extremity deep vein thrombosis in patients with cancer: A systematic review and meta-analysis","volume":"22","author":"Wang","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"102359","DOI":"10.1016\/j.jvsv.2025.102359","article-title":"Treatment of catheter related thrombosis: A systematic review, meta-analysis, and national survey","volume":"14","author":"Oomen","year":"2026","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1182\/blood.2025030790","article-title":"How I treat breakthrough thrombosis in patients with cancer","volume":"147","author":"Marx","year":"2026","journal-title":"Blood"},{"key":"ref_101","first-page":"419","article-title":"Prediction and management of recurrent venous thromboembolism in patients with cancer","volume":"5","author":"Wang","year":"2026","journal-title":"Bleeding Thromb. Vasc. Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/eurheartj\/ehaf453","article-title":"Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: A meta-analysis","volume":"47","author":"Khan","year":"2026","journal-title":"Eur. Heart J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/a-2418-3960","article-title":"Risk of recurrent venous thromboembolism in patients with cancer: An individual patient data meta-analysis and development of a prediction model","volume":"125","author":"Lanting","year":"2025","journal-title":"Thromb. Haemost."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"103278","DOI":"10.1016\/j.rpth.2025.103278","article-title":"The Ottawa score for prediction of recurrent venous thromboembolism in cancer patients treated with tinzaparin: An individual patient data meta-analysis","volume":"10","author":"Chapelle","year":"2026","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejim.2025.04.016","article-title":"Derivation and validation of the Caravaggio score for the risk stratification for recurrence in patients with cancer-associated venous thromboembolism","volume":"137","author":"Vedovati","year":"2025","journal-title":"Eur. J. Intern. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.thromres.2023.06.015","article-title":"Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning","volume":"228","author":"Souto","year":"2023","journal-title":"Thromb. Res."},{"key":"ref_107","first-page":"e319-28","article-title":"Prediction of major bleeding in anticoagulated patients for venous thromboembolism: Comparison of the RIETE and the VTE-BLEED scores","volume":"5","author":"Lecumberri","year":"2021","journal-title":"TH Open"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1183\/13993003.00280-2016","article-title":"Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment","volume":"48","author":"Klok","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3324\/haematol.2019.222828","article-title":"Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: A systematic review and meta-analysis","volume":"105","author":"Delluc","year":"2020","journal-title":"Haematologica"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/jth.14783","article-title":"Prognosis in patients with cancer-associated venous thromboembolism: Comparison of the RIETE-VTE and modified Ottawa score","volume":"18","author":"Pfaundler","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1016\/j.jtha.2025.08.007","article-title":"External validation of the VTE-PREDICT score for predicting recurrence and bleeding in venous thromboembolism: Results from the Registro Informatizado Enfermedad TromboEmb\u00f3lica Registry","volume":"23","author":"Hoberstorfer","year":"2025","journal-title":"J. Thromb. Haemost."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1677\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:22:28Z","timestamp":1788927748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":111,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["medicina62091677"],"URL":"https:\/\/doi.org\/10.3390\/medicina62091677","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}